Best GLP-1 on CVS Caremark Formulary in 2026 (and What Just Changed)

For most people using CVS Caremark for weight loss today, Wegovy is the drug to check first, because it’s the preferred covered option until Zepbound returns on October 1, 2026. If you want a pill, watch for Foundayo on June 1. If you have type 2 diabetes, the diabetes GLP-1s like Ozempic and Mounjaro are a separate, usually easier path. There is no single “best” GLP-1 for everyone — the best one is the covered drug that costs you the least after approval.

Here’s the full CVS Caremark GLP-1 picture in one place — the weight-loss drugs (Wegovy preferred now, Foundayo coverable June 1, Zepbound returning Oct 1) and the diabetes drugs (Ozempic, Mounjaro, Rybelsus, Trulicity). Diabetes GLP-1s are covered far more widely than weight-loss ones, and nearly all of these need prior authorization.

The only reliable way to know your real coverage is to check your own plan — and you have two ways to do it. You can look it up yourself on Caremark.com using their “Check Drug Cost & Coverage” tool, or you can run a free coverage check that does it for you. Both tell you whether a drug is covered, what it may cost, and whether you’ll need prior approval.

CVS Caremark changed its GLP-1 coverage because drug makers and pharmacy middlemen are in a price war, and patients got caught in it. In 2025, CVS Caremark cut Zepbound and made Wegovy the preferred weight-loss drug. After a year of patient backlash, a class-action lawsuit, and new manufacturer negotiations, CVS reversed course: on May 28, 2026 it announced Zepbound returns as a preferred option on October 1, 2026, and the new pill Foundayo becomes coverable June 1, 2026 where plans approve coverage.

CVS Caremark treats GLP-1s in two separate lanes. For type 2 diabetes, drugs like Ozempic and Mounjaro are covered on almost every plan with a diagnosis and prior approval. For weight loss, Wegovy (and soon Zepbound and Foundayo) are only covered if your employer chose to cover obesity drugs — and many don’t. Same medicine, completely different coverage odds.

Ozempic and Wegovy both contain the same medicine — semaglutide — but they’re approved for different uses and travel through different coverage doors. Mounjaro and Zepbound are the same story with tirzepatide. They are not interchangeable — your plan covers them based on why they’re prescribed and which label they carry, not just the molecule inside.

For most CVS Caremark members chasing weight-loss coverage before October 1, 2026, Wegovy is the most practical first drug to check, because it’s the preferred covered option. Wegovy is FDA-approved for chronic weight management, comes as a weekly shot or a daily pill, and its shot also carries an approved heart-protection use for some people.

Zepbound coverage depends on timing. Right now, it’s off CVS Caremark’s standard formulary — but CVS announced it returns as a preferred option on October 1, 2026. Before that date, you’d usually need a formulary exception. After that date, Zepbound becomes a strong first choice again for covered plans.

Foundayo is the new oral GLP-1 to watch. It’s an FDA-approved weight-loss pill (approved April 1, 2026) you take once a day, with no food or timing rules. CVS Caremark said the “new drug” block on Foundayo lifts June 1, 2026 — but only for plans that choose to cover it, and you’ll still need prior approval.

Foundayo’s generic name is orforglipron. Unlike the oral semaglutide pill, it can be taken any time of day without food or water restrictions. Like all GLP-1s, it carries a boxed warning about a rare thyroid tumor risk, so it’s not for people with a personal or family history of medullary thyroid cancer or MEN 2.

For weight-loss GLP-1s, CVS Caremark’s prior-authorization criteria focus on your BMI, any weight-related conditions, a diet-and-activity plan, and documented participation in a weight-management program. To renew, plans want proof the drug is working. Gather these before your appointment and your odds of a fast yes go way up.

The right move after a denial depends on why you were denied. A missing document, a plan exclusion, a “try Wegovy first” rule, and a high deductible all need different responses. Match the reason to the fix below before you panic or pay full price.

If you’d rather not handle the insurance maze alone, the best telehealth path for CVS Caremark members is the one that checks your coverage and handles the prior-authorization paperwork for FDA-approved, brand-name GLP-1s. We recommend Ro first for that job, with Sesame Care as a solid backup if your plan won’t cover the drug and you want a low cash price. And to be clear — you don’t need any telehealth company to use your own insurance. Your own doctor works too.

If the prescription is for the same FDA-approved branded drug and dose, your CVS Caremark benefit decides your coverage and cost — not whether Ro or your regular doctor wrote it. So this isn’t about getting the drug. It’s about who fights the paperwork.

No public page — including this one — can know your exact plan, your copay, your deductible, or whether your employer chose to cover weight-loss drugs. That’s not us dodging the question. It’s the honest limit of any website, because CVS Caremark lets every employer customize the list. The real answer is a workflow, not a promise.